Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma
Abstract Glioblastoma (GBM) is an aggressive and incurable tumor of the brain with limited treatment options. Current first-line standard of care is the DNA alkylating agent temozolomide (TMZ), but this treatment strategy adds only ~4 months to median survival due to the rapid development of resista...
Guardado en:
Autores principales: | D. M. Tiek, J. D. Rone, G. T. Graham, E. L. Pannkuk, B. R. Haddad, R. B. Riggins |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d04b39e1ba5c4c6ea68bb0a9360fff81 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Integrated genetic and metabolic landscapes predict vulnerabilities of temozolomide resistant glioblastoma cells
por: Selva Rupa Christinal Immanuel, et al.
Publicado: (2021) -
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Xiaoyue Chen, et al.
Publicado: (2018) -
Interplay of m6A and histone modifications contributes to temozolomide resistance in glioblastoma
por: Fuxi Li, et al.
Publicado: (2021) -
Novel cancer stem cell marker MVP enhances temozolomide-resistance in glioblastoma
por: Kum Hee Noh, et al.
Publicado: (2022) -
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
por: Thomas RP, et al.
Publicado: (2012)